Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.

Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA.

Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25605. [Epub ahead of print] No abstract available.

PMID:
31379016
2.

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1. doi: 10.1016/j.clml.2019.05.008. Epub 2019 May 13.

3.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.

Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31175001
4.

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.

Galkin M, Jonas BA.

Core Evid. 2019 Apr 26;14:3-17. doi: 10.2147/CE.S172912. eCollection 2019.

5.

Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science.

Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW.

Toxics. 2019 May 9;7(2). pii: E27. doi: 10.3390/toxics7020027. Review.

6.

Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.

Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA.

Nanomedicine. 2019 Aug;20:102004. doi: 10.1016/j.nano.2019.04.007. Epub 2019 May 2.

PMID:
31055076
7.

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA.

Am J Hematol. 2019 Jul;94(7):803-811. doi: 10.1002/ajh.25484. Epub 2019 May 1. Review.

8.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A.

Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.

9.

Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.

Scharadin TM, Malfatti MA, Haack K, Turteltaub KW, Pan CX, Henderson PT, Jonas BA.

Chem Res Toxicol. 2018 Oct 15;31(10):1042-1051. doi: 10.1021/acs.chemrestox.8b00107. Epub 2018 Sep 10.

PMID:
30152692
10.

New and emerging therapies for acute myeloid leukaemia.

Davis JR, Benjamin DJ, Jonas BA.

J Investig Med. 2018 Dec;66(8):1088-1095. doi: 10.1136/jim-2018-000807. Epub 2018 Aug 19.

PMID:
30127098
11.

Complications and early mortality in patients with acute promyelocytic leukemia treated in California.

Ho G, Li Q, Brunson A, Jonas BA, Wun T, Keegan THM.

Am J Hematol. 2018 Nov;93(11):E370-E372. doi: 10.1002/ajh.25252. Epub 2018 Sep 26. No abstract available.

PMID:
30105792
12.

Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.

Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T.

J Natl Cancer Inst. 2019 Jan 1;111(1):78-85. doi: 10.1093/jnci/djy073.

13.

Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio.

Wung W, Ananthakrishnan S, Jonas BA.

J Investig Med High Impact Case Rep. 2018 Mar 14;6:2324709618764207. doi: 10.1177/2324709618764207. eCollection 2018 Jan-Dec.

14.

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.

Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM.

Cancer. 2018 May 1;124(9):1938-1945. doi: 10.1002/cncr.31296. Epub 2018 Feb 16.

15.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA.

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

PMID:
29339097
16.

Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia.

Kjelland JD, Dwyre DM, Jonas BA.

Case Rep Hematol. 2017;2017:3625946. doi: 10.1155/2017/3625946. Epub 2017 Oct 11.

17.

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.

Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA.

Blood Cancer J. 2017 Sep 8;7(9):e605. doi: 10.1038/bcj.2017.81.

18.

On the origin of relapse in AML.

Jonas BA.

Sci Transl Med. 2017 Jul 12;9(398). pii: eaan8205. doi: 10.1126/scitranslmed.aan8205.

19.

A new therapeutic target for myelofibrosis is cause for Gli.

Jonas BA.

Sci Transl Med. 2017 May 31;9(392). pii: eaan4297. doi: 10.1126/scitranslmed.aan4297.

20.

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM.

Br J Haematol. 2017 Jul;178(1):72-80. doi: 10.1111/bjh.14638. Epub 2017 May 25.

21.

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.

Jonas BA.

Sci Transl Med. 2017 Apr 19;9(386). pii: eaan2781. doi: 10.1126/scitranslmed.aan2781.

22.

Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.

Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM.

Br J Haematol. 2017 Jun;177(5):791-799. doi: 10.1111/bjh.14631. Epub 2017 Apr 17.

23.

From MDS/AML to iPSC and back again.

Jonas BA.

Sci Transl Med. 2017 Mar 8;9(380). pii: eaam9861. doi: 10.1126/scitranslmed.aam9861.

24.

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Erratum in: Leuk Res. 2017 Aug;59:65.

PMID:
27736729
26.
27.

Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.

Jonas BA, Medeiros BC.

Oncology (Williston Park). 2016 Apr;30(4):330, 333. No abstract available.

28.

Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome.

Ali SF, Sonu RJ, Dwyre DM, Jonas BA, Rashidi HH.

Case Rep Hematol. 2015;2015:318545. doi: 10.1155/2015/318545. Epub 2015 Dec 21.

29.

Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis.

Stelling A, Jonas BA, Rashidi HH, Abedi M, Chen M.

Cancers (Basel). 2015 Dec 14;7(4):2459-65. doi: 10.3390/cancers7040903.

30.

B lymphoblastic leukemia with granules mimicking acute myeloid leukemia.

Song JY, Khojeini EV, Dwyre DM, Jonas BA.

Int J Hematol. 2015 Sep;102(3):251-2. doi: 10.1007/s12185-015-1842-9. Epub 2015 Jul 18. No abstract available.

31.

Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature.

Sonu RJ, Jonas BA, Dwyre DM, Gregg JP, Rashidi HH.

Case Rep Hematol. 2015;2015:458052. doi: 10.1155/2015/458052. Epub 2015 Apr 8.

32.

Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.

McCoach CE, Rogers JG, Dwyre DM, Jonas BA.

Cancer Treat Commun. 2015;4:15-18. No abstract available.

33.

MDS prognostic scoring systems – past, present, and future.

Jonas BA, Greenberg PL.

Best Pract Res Clin Haematol. 2015 Mar;28(1):3-13. doi: 10.1016/j.beha.2014.11.001. Epub 2014 Nov 11. Review.

34.

Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX.

Nanomedicine (Lond). 2014;9(12):1807-20. doi: 10.2217/nnm.14.44. Epub 2014 Mar 17.

35.

Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Goodson ML, Mengeling BJ, Jonas BA, Privalsky ML.

J Biol Chem. 2011 Dec 30;286(52):44988-99. doi: 10.1074/jbc.M111.291625. Epub 2011 Nov 7.

37.

Corepressors: custom tailoring and alterations while you wait.

Goodson M, Jonas BA, Privalsky MA.

Nucl Recept Signal. 2005;3:e003. Epub 2005 Oct 21.

38.
39.

SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways.

Jonas BA, Privalsky ML.

J Biol Chem. 2004 Dec 24;279(52):54676-86. Epub 2004 Oct 18.

Supplemental Content

Loading ...
Support Center